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Background: Idiopathic pulmonary fibrosis (IPF) is a progressive disease of insidious onset, and is responsible for
up to 30,000 deaths per year in the U.S. Excessive production of extracellular matrix by myofibroblasts has been
shown to be an important pathological feature in IPF. TGF-β1 is expressed in fibrotic lung and promotes fibroblast
to myofibroblast differentiation (FMD) as well as matrix deposition.
Methods: To identify the mechanism of Arsenic trioxide’s (ATO)’s anti-fibrotic effect in vitro, normal human lung
fibroblasts (NHLFs) were treated with ATO for 24 hours and were then exposed to TGF-β1 (1 ng/ml) before
harvesting at multiple time points. To investigate whether ATO is able to alleviate lung fibrosis in vivo, C57BL/6 mice
were administered bleomycin by oropharyngeal aspiration and ATO was injected intraperitoneally daily for 14 days.
Quantitative real-time PCR, western blotting, and immunofluorescent staining were used to assess the expression of
fibrotic markers such as α-smooth muscle actin (α-SMA) and α-1 type I collagen.
Results: Treatment of NHLFs with ATO at very low concentrations (10-20nM) inhibits TGF-β1-induced α-smooth
muscle actin (α-SMA) and α-1 type I collagen mRNA and protein expression. ATO also diminishes the
TGF-β1-mediated contractile response in NHLFs. ATO’s down-regulation of profibrotic molecules is associated with
inhibition of Akt, as well as Smad2/Smad3 phosphorylation. TGF-β1-induced H2O2 and NOX-4 mRNA expression are
also blocked by ATO. ATO-mediated reduction in Smad3 phosphorylation correlated with a reduction of
promyelocytic leukemia (PML) nuclear bodies and PML protein expression. PML-/- mouse embryonic fibroblasts
(MEFs) showed decreased fibronectin and PAI-1 expression in response to TGF-β1. Daily intraperitoneal injection of
ATO (1 mg/kg) in C57BL/6 mice inhibits bleomycin induced lung α-1 type I collagen mRNA and protein expression.
Conclusions: In summary, these data indicate that low concentrations of ATO inhibit TGF-β1-induced fibroblast to
myofibroblast differentiation and decreases bleomycin induced pulmonary fibrosis.
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Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive and fatal disease [1]. A recent study indicated that
the 5-year survival of IPF ranges from 30% - 50%. Des-
pite tremendous progress in our understanding of the
pathogenesis of IPF, no effective medicinal treatment has
been shown to improve the mortality in afflicted patients
[2]. A prominent pathological feature of IPF is the for-
mation of fibrotic foci, which consist of myofibroblasts
and the extracellular matrix which they produce. Myofi-
broblasts are the principle effecter cells synthesizing
pro-fibrotic proteins such as α-SMA, type I collagen,
and fibronectin. Although multiple types of cells can dif-
ferentiate into myofibroblasts, fibroblast to myofibro-
blast differentiation (FMD) is the major source for
myofibroblast accumulation [3].
Transforming growth factor (TGF)-β1 is a potent
fibrogenic cytokine and plays a crucial role in the patho-
genesis of pulmonary fibrosis [4]. TGF-β1 induces FMD
by activating Smad3 and Akt signaling pathways [5,6].
Over-expression of TGF-β1 using of a recombinant
adenovirus vector carrying an active TGF-β1 construct is
sufficient to induce pulmonary fibrosis in vivo [4]. In
addition, interventions that inhibit TGF-β1 signaling
have been shown to block the development pulmonary
fibrosis in animal models [7]. To date there are no ap-
proved therapies to target TGF-β1 for the treatment of
pulmonary fibrosis, so furthering our understanding of
the profibrotic effects of TGF-β1 may lead to an effective
therapy for pulmonary fibrosis.
Arsenic trioxide (ATO) has been used as a drug for
more than 2000 years for the treatment of diseases in-
cluding ulcers, psoriasis, and malaria [8]. In the modern
era, arsenic has been shown to be effective for the treat-
ment of various cancers, especially acute promyelocytic
leukemia (APL) [9,10]. Recent studies have shown that
ATO can regulate the expression of various proteins as
well as pathways involved with TGF-β1 signaling. For ex-
ample, ATO induces SnoN/SkiL, an inhibitory TGF-β1
regulator by affecting Smad3 nuclear transportation in
ovarian carcinoma cells [11]. ATO has also been re-
ported to induce TG-interacting factor (TGIF), which is
another well-characterized Smad co-repressor for TGF-
β1 responsive genes. Interestingly, ATO also degrades
promyelocytic leukemia (PML) nuclear bodies and PML
protein expression in various cancer cell lines [12].
PML was originally identified as a fusion partner of ret-
inoic acid receptor alpha (RARα) in APL patients [13].
PML protein contains an N-terminus RING finger, two
B-boxes and a coiled-coil domain, which are encoded by
the first 3 exons of the PML gene. Seven different iso-
forms differ from each other in the C-terminus, which are
generated by alternative splicing from exon 4 to exon 9.
PML proteins exist in both the cytoplasm and nucleus.However, the majority of PML protein locates to the nu-
cleus and forms complicated protein structures known as
PML nuclear bodies. PML nuclear bodies are dynamic
structures with diameters ranging from 200 nm to 1 μm.
They exist in almost all mammalian cells and play import-
ant roles in DNA damage repair, transcription regulation,
viral defense, control of apoptosis and senescence [14,15].
PML may also regulate TGF-β1 signaling, as cytoplasmic
PML (cPML) has been shown to aid with Smad3 phos-
phorylation in mouse embryonic fibroblasts (MEFs) by fa-
cilitating interactions among Smad anchor for receptor
activation (SARA), Smad3 and the Type-I TGF-β1 recep-
tor [16]. However, to date the role of PML in TGF-β1-
induced FMD and lung fibrosis in vivo has not been
addressed.
To better understand the potential effect of ATO in
regulating TGF-β1-induced FMD and lung fibrosis, we
investigated how TGF-β1 signaling pathways were regu-
lated in normal human lung fibroblasts (NHLFs) in re-
sponse to treatment with ATO. We observed that ATO
inhibited TGF-β1 signaling by inhibition of Smad2/
Smad3 and Akt phosphorylation. We also examined the
anti-fibrotic effect of ATO in vivo by using a murine
bleomycin model of pulmonary fibrosis, and found that
intraperitoneal administration of ATO reduced bleo-
mycin induced pulmonary fibrosis in C57/BL6 mice.Methods
Reagents and antibodies
Arsenic trioxide (Sigma-Aldrich) was prepared in 1 N
NaOH at 250 mM and then diluted in sterile water for a
stock concentration of 1 μM. Cell culture medium, FGM-
2 and DMEM, were purchased from Lonza (Allendale,
NJ) and Gibco. Human recombinant TGF-β1 was pur-
chased from R&D systems (Minneapolis, MN). Antibodies
used were: alpha-SMA (Sigma-Aldrich, 1:10,000), type-1
collagen (abcam, 1:2000), PML (Santa Cruz, 1:500),
PAI-1 (peprotech, 1:2000), fibronectin (BD science,
1:500). Antibodies for Smad2, p-Samd2, Smad3, p-
Smad3, Akt, p-Akt, Erk, p-Erk, p38, p-p38 were pur-
chased from Cell signaling and used at a concentration
of 1:1000.Cell culture
Normal human lung fibroblasts (NHLFs) were purchased
from Lonza (Allendale, NJ). Cells were maintained in
FGM-2 (Lonza) and only early passage cells (before pas-
sage 6) were used for all experiments. Wild-typed and
PML -/- mouse embryonic fibroblasts (MEFs) were a kind
gift from the laboratory of Dr. Pier Paolo Pandolfi (Beth
Israel Deaconess Cancer Center) and maintained in
DMEM with 20% FBS and 1% penicillin-streptomycin
(Gibco). Human lung fibroblasts from control patients
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Western blot analysis
Cells were harvested using 1x RIPA buffer (Cell signaling)
with 1 mM PMSF (Sigma Aldrich). Thirty μg of protein
per sample was loaded onto 4–12% Novex Tris-Glycine
SDS polyacrylamide gels (Invitrogen) for electrophoresis
and then transferred on polyvinylidene difluoride (PVDF)
membranes (0.45 μm, Invitrogen). Membranes were then
blocked in 5% Milk (BioRad) for 1 hour at room
temperature and then incubated with the appropriate
primary antibody overnight. Secondary antibodies and
an ECL kit from (GE) were applied for generating
chemiluminescent signals. All western blot data repre-
sents triplicate repeats. Densitometry analysis was per-
formed using National Institutes of Health (NIH)
ImageJ software.
Real time quantitative PCR
Real time quantitative PCR was performed using the iCy-
cler (Bio-Rad Laboratories, Hercules, CA), and SYBR
green supermix (Bio-Rad) was employed according to the
manufacturer’s instructions. mRNA expression was cor-
rected to expression of the 36B4 housekeeping gene. Pri-
mer sequences that were employed were: h-α-SMA: Fwd:
GAAGAAGAGGACAGCACT, Rev: TCCCATTCCCACC
ATCAC; m-α-SMA: Fwd: TGCTGACAGAGGCACCAC
TGAA, Rev: CAGTTGTACGTCCAGAGGCATA; h-Coll
agen-1: Fwd: CGGAGGAGAGTCAGGAAGG, Rev: CAC
AAGGAACAGAACAGAACA; m-Collagen-1: Fwd: GCC
AAGAAGACATCCCTGAAG, Rev: TCATTGCATTGCA
CGTCATC; 36B4: Fwd: CGACCTGGAAGTCCAACTAC;
Rev: ATCTGCTGCATCTGCTTG; h-CTGF: Fwd: GGCT
TACCGACTGGAAGAC, Rev: AGGAGGCGTTGTCA
TTGG; h-PAI-1: Fwd: GGCTGGTGCTGGTGAATGC;
Rev: AGTGCTGCCGTCTGATTTGTG.
Rat tail type I collagen gel contraction assay
Rat tail type I collagen gel contraction assay was con-
ducted as previously described [17]. Briefly, a 12-well
cell culture plate was pre-coated with 5% sterile BSA for
4 hours. Rat tail type-I collagen (354236 BD biosciences)
was diluted with fibroblast basal medium (FBM, Lonza,
CC-3131) with 0.5% BSA into 2 mg/ml and mixed with
NHLFs to reach a final concentration of 2 × 105 cells/ml.
One N NaOH was added as per the manufacture’s in-
struction. Eight hundred microliters of cell-collagen
mixture were then added into each well of the culture
plate and incubated at 37° for 30 minutes. Cells were in-
cubated in FBM medium with 0.5% BSA overnight. Cells
were treated with arsenic trioxide and TGF-β1 as indi-
cated. Gel sizes were measured using the National In-
stitutes of Health (NIH) ImageJ software. To harvestthe cells from the gel, a type I collagenase (Invitrogen)
was applied to dissolve the collagen gel. Briefly, trypsin
was added onto the gels for 5 minutes. Type I collage-
nase (5 mg/ml) was then added onto the gels and they
were incubated at 37° for 30 minutes. Cells were spun
down and lysed using RIPA buffer for western blot
analysis.Immnofluorescent staining
NHLFs were plated into 8 well chamber slides and
treated as indicated. After washing in PBS for 5 minutes,
cells were fixed by 4% paraformaldehyde (Electron Mi-
croscopy Sciences) for 10 minutes. Fixed cells were then
washed in HBSS for 5 minutes 3 times before a blocking
buffer (5% Goat serum + 0.5% BSA + 0.4% Triton X-100)
was added for 1 hr at room temperature. Appropriate
primary antibodies and secondary antibodies were then
added for one hr at room temperature. A 10 minute
HBSS wash times 3 was performed prior to the addition
of the secondary antibody. DAPI (Invitrogen) was added
for nuclear staining and prolong gold (Invitrogen) was
used for preserving the signal.
For processing paraffin embedded tissue slides, slides
were incubated at 60°C for 45 min. Then slides were de-
paraffinized by immersion in xylene and re-hydrated.
Following hydration, slides were boiled in 1x SSC for
10mins for antigen retrieval. After boiling slides were
kept in hot SSC for 30 mins. at room temperature. Slides
were then washed in 50 μM ammonium chloride for 10
mins., then rinsed in PBS for 10 mins. 3 times prior to
application of the primary antibody.MTT assay
An in vitro toxicology assay kit (Sigma Aldrich) was
used for this experiment. Briefly, NHLFs were plated
into a 12-well plate and pretreated with ATO (10nM,
20nM) for 48 hrs. Cells were then washed with HBSS
prior to addition of 1 ml of FGM. MTT (M-5655, Sigma
Aldrich) was added into to media and cells were incu-
bated at 37°C for 2 hrs. Thereafter, the culture media
was removed and MTT Solubilization Solution (M-
8910, Sigma Aldrich) was added. Absorbance of each
well was measured at the wavelengths of 570 nm and
690 nm.H2O2 detection
NHLFs were treated with ATO and TGF-β1 as indicated.
Then cells were incubated with 30 μM DCFH-DA at 37°
C for 30 min. and washed with HBSS several times. Cells
were lysed in 1 N NaOH and the intensity of fluores-
cence was determined using a plate reader with an exci-
tation filter at 485 nm and an emission filter at 535 nm.
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intensity of each sample.
Cytoplasmic and nuclear protein extraction
Proteins from cytoplasm and nucleus compartments
were separated by using NE-PER Nuclear and Cytoplas-
mic Extraction Reagents (Thermo scientific, #78835).
Briefly, NHLFs were harvested with trypsin-EDTA and
then washed twice with PBS. Then cells were centri-
fuged at 500 × g for 5 minutes and supernatants were
removed. Ice cold CER-I and CER-II solutions were
added per the manufacturer’s instructions to separate
the cytoplasmic from the nuclear compartment pro-
teins. Western blot for GAPDH and histone 3 were used
to ensure there was no contamination in each part of
the extracts.
Bleomycin and ATO treatment
All protocols for animal studies were approved by the
Institutional Animal Care and Use Committee of Tulane
University. C57/BL6 mice (Charles River) were separated
into 5 groups with 7 mice in each group. Two days be-
fore bleomycin exposure, arsenic trioxide (1 mg/kg) was
administered daily by intraperitoneal injection in the
ATO-pretreatment group. PBS with the same amount of
NaOH employed to solubilize the ATO was used as a
control for other groups. Bleomycin (Zhejiang Hisun
Pharmaceutical Co., Ltd, 2units/kg) was given by oro-
pharyngeal aspiration as described previously (25). For
the ATO-delayed treatment group, ATO was adminis-
tered daily starting on day 6 following bleomycin admin-
istration. Mice were sacrificed on day 14 after
administration of bleomycin. Left lungs were fixed for
trichrome staining and right lungs were harvested and
homogenized in liquid nitrogen for real time quantitative
PCR and western blot analysis.
Total collagen quantification
Left lungs were paraffin-embedded and tissue slides
were prepared for trichrome staining. An Aperio slide
scanner (Aperio, CA) was used to scan the tissue slides
per the manufacturer’s instruction. The whole lung tis-
sue section on a single slide was scanned and collagen
content was calculated using an internal PPC Collagen
(2) RWB program. A ratio of total positive value to the
total number value was used to represent collagen
expression.
Statistic anaylysis
Statistic analysis was conducted using ANOVA followed
by the Bonferroni post hoc test. Data are presented as
the mean (±SEM) and represent multiple experiments
performed in triplicate.Results
ATO inhibits TGF-β1 induced fibrotic markers
Myofibroblasts play a crucial role in formation of fibro-
blastic foci [3]. TGF-β1 induces FMD and increases α-
SMA and type I collagen expression. To examine
whether ATO inhibits TGF-β1-induced FMD, NHLFs
were pretreated with very low concentrations of ATO
(10nM or 20nM) for 24 hrs and then exposed to TGF-
β1 (1 ng/ml) for another 24 hrs. α-SMA and type I colla-
gen mRNA expression were induced by TGF-β1 (α-SMA:
29.90 ± 5.45; Col-1: 18.02 ± 1.85; p < 0.05), however these
effects were diminished by ATO treatment (α-SMA:
14.76 ± 1.38 & 8.47 ± 2.06 vs. 29.90 ± 5.45; p < 0.05;
Col-1: 9.10 ± 0.40 & 6.52 ± 0.52 vs. 18.02 ± 1.85; p <0.05)
(Figure 1A, 1B). Connective tissue growth factor
(CTGF) and plasminogen activation inhibitor 1 (PAI-1)
were also induced by TGF-β1 (CTGF: 21.73 ± 1.54; PAI-
1: 54.40 ± 5.48; p < 0.05) and are thought to play import-
ant roles in pulmonary fibrosis [6,18]. Pretreatment of
ATO decreased TGF-β1-induced expression of CTGF
and PAI-1 mRNA (CTGF: 12.47 ± 1.60 vs. 21.73 ± 1.54;
p < 0.05; PAI-1: 29.19 ± 3.95 vs. 54.40 ± 5.48; p < 0.05)
(Figure 1C, 1D). Western blots were performed on pro-
teins derived from duplicate wells. α-SMA and type I
collagen protein expression were induced by TGF-β1,
and pretreatment with ATO diminished this effect
(Figure 1E). Furthermore, ATO (10nM, 20nM) blocked
TGF-β1 induced α-SMA and type I collagen protein
expression in fibroblasts extracted from control and
IPF patient lungs (Additional file 1: Figure S1A, S1B).
A delayed ATO treatment experiment in which ATO
(10nM, 20nM) was given to NHLFs after 24 hrs of
TGF-β1 (1 ng/ml) exposure also blocked TGF-β1 in-
duced α-SMA and type I collagen protein expression
(Additional file 1: Figure S1C).
NHLFs have a spindle-shaped morphology while myofi-
broblasts are more stellar shaped cells and express α-SMA
in fibrils [19]. NHLFs were pretreated with ATO (10nM,
20nM) for 24 hrs and then treated with TGF-β1 (1 ng/ml)
for another 24 hrs, to test whether ATO affects TGF-β1-
induced. α-SMA fiber formation. Immunofluorescent
staining demonstrated that ATO pretreatment decreased
TGF-β1 induced incorporation of α-SMA into fibrils
(Figure 1F). ATO is a well-characterized inducer of apop-
tosis in APL as well as non-malignant cell lines [20,21].
Recent studies have shown that ATO induces pulmonary
fibroblast growth inhibition at a concentration of 50 μM
[22]. However the concentration of ATO used in our stud-
ies are several orders of magnitude lower than the concen-
tration employed in the manuscripts mentioned above. To
examine whether 10nM or 20nM concentrations of ATO
inhibit NHLF cell viability, cells were treated with ATO
for 48 hrs and protein was harvested for western blot. An
MTT assay revealed no significant differences in cell
Figure 1 ATO inhibits TGF-β1-induced α-SMA and collagen expression. (A-D) Normal human lung fibroblasts (NHLFs) were serum starved
overnight and treated with Arsenic trioxide (ATO) for 24 hrs, then treated with TGF-β1 (1 ng/ml) for 24 hrs. α-SMA, Collagen-1, PAI-1 and CTGF
mRNA expression levels were evaluated by TGF-β1 and ATO inhibited TGF-β1’s effect. (E) TGF-β1-induced α-SMA and collagen-1 protein
expression was blocked by ATO in NHLFs. (F) Immunofluorescent staining showed TGF-β1-induced α-SMA fiber formation was reduced by ATO.
(G) An MTT assay showing that ATO does not affect NHLF viability. RT-PCR Data represent results from three independent experiments with
duplicate repeats. Western blot and immunofluoresent staining data represent consistent trend in three independent repeats with the best image
quality. *P value < 0.05, **P value <0.01, ***P value < 0.001.
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tions of ATO (Figure 1G).
ATO inhibits TGF-β-induced fibroblast contractile activity
Myofibroblasts have greater contractile activity com-
pared to fibroblasts owing to the elevated expression
level of α-SMA [23]. A type I collagen gel contraction
assay was conducted to assess whether ATO regulates
TGF-β1-induced contraction in NHLFs, NHLFs were
cultured in type-I collagen gel as described in Methods.Cells were pretreated with ATO (10nM or 20nM) for
24 hrs and then treated with TGF-β1 (1 ng/ml) for an-
other 48 hrs. Treatment with TGF-β1 resulted in a de-
crease in the size of the collagen gel (78% ± 2%; p <
0.05), indicative of an increase in contractility, whereas
pretreatment of ATO blocked this effect (89% ± 5% &
104% ± 4% vs. 78% ± 2%; p < 0.05) (Figure 2A, 2B). We
also harvested the NHLFs from collagen gels to correl-
ate the contractile activity with α-SMA expression.
Western blot demonstrated that TGF-β1 increases α-
Figure 2 ATO inhibits TGF-β-induced fibroblast contractile activity in rat tail type-I collagen gel. (A) NHLFs were cultured in rat tail type I
collagen gels (2 mg/ml) and pre-treated with ATO for 24 hrs. Cells were exposed to TGF-β1 (1 ng/ml) for another 48 hrs. TGF-β1treatment
decreased the size of the gel while ATO pre-treatment blocked the reduction in gel size. (B) A summation of the percentage of gel surface area
in each well of Figure 2A to the control gel surface area. (C) NHLFs were cultured in rat tail type I collagen gels and treated as described above.
Gels were digested using type-I collagenase (5 mg/ml) and cells were harvested in SDS loading buffer for western blot. α-SMA protein expression
was induced by TGF-β1 and ATO abrogated the induction. Data represent results from three independent experiments with triplicate repeats.
*P value < 0.05, **P value <0.01, ***P value < 0.001.
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inhibits this effect (Figure 2C).
ATO inhibits Smad2/Smad3 and Akt phosphorylation
TGF-β1 induces FMD by activating Smad2/3 and Akt
phosphorylation [5,6]. To investigate TGF-β1 signaling
pathways that may be affected by ATO, we pretreated
NHLFs with ATO (10nM or 20nM) for 24 hrs and then
treated the cells with TGF-β1 for 30 mins. TGF-β1 in-
duced Smad2/Smad3 phosphorylation, however, the level
of phosphorylation was decreased in the ATO pretreat-
ment group (Figure 3A, 3B). To investigate whether the
effect of ATO on Smad phosphorylation was on account
of ATO inactivating TGF-β1 in cell culture medium,
NHLFs were pretreated with ATO (10nM or 20nM) for
24 hrs, then the cells were washed 5 times with PBS to
remove ATO from the media prior to the addition of
TGF-β1. Smad2/Smad3 phosphorylation was inhibited
when ATO was removed prior to treatment with TGF-
β1 (Figure 3C). This indicates that the inhibitory effects
of ATO on TGF-β1 Smad phosphorylation were not due
to chemical inactivation of the TGF-β1 ligand. Next we
investigated the effects of ATO on TGF-β1-induced Akt
phosphorylation. NHLFs were pretreated with ATO for
24 hrs and then exposed to TGF-β1 for another 12 hrs.
Pretreatment of ATO decreased TGF-β1-mediated Akt
phosphorylation (Figure 3D).
To assess whether ATO down-regulates TGF-β1-
driven phosphorylation on a global level, we also evalu-
ated P38 phosphorylation, which is also involved inTGF-β1 signaling [24]. NHLFs were pretreated with
ATO (10nM or 20nM) for 24 hrs and treated with TGF-
β1 for 30 mins. p38 phosphorylation was induced by
TGF-β1 and ATO pretreatment did not diminish its
phosphorylation (Figure 3E). This indicates that ATO
does not globally affect phosphorylation. Erk phosphor-
ylation was also assessed, however, we did not observe
an increase in Erk phosphorylation in the NHLFs in re-
sponse to TGF-β1 over several time points, nor a dimin-
ution in the baseline Erk phosphorylation in response to
ATO.
ATO blocks TGF-β1 induced H2O2 and NOX-4 mRNA
expression
Reactive oxygen species (ROS), especially H2O2 plays an
important role in the derivation of TGF-β1-mediated fi-
brotic phenotypes [18]. To investigate whether low doses
of ATO regulate H2O2 levels in NHLFs, we pretreated
the cells with ATO (10nM or 20nM) for 24 hrs and then
exposed them to TGF-β1 for another 12 hrs. These low
concentrations of ATO did not induce H2O2 (0.81 ± 0.04
& 0.77 ± 0.04; p > 0.05), and to the contrary, TGF-β1-
induced H2O2 expression was blocked by ATO (1.11 ±
0.04 & 0.95 ± 0.07 vs. 1.49 ± 0.06; p < 0.05) (Figure 3F).
To investigate whether ATO down-regulated TGF-β1 in-
duced Smad3 phosphorylation by reducing H2O2 expres-
sion, NHLFs were pretreated with ATO (20nM) for
24 hrs and then exposed to TGF-β1 with or without
H2O2 (100 μM, 200 μM, and 300 μM) for an addional
30 mins. H2O2 (100 μM) partially restored Smad3
Figure 3 (See legend on next page.)
Luo et al. Respiratory Research 2014, 15:51 Page 7 of 14
http://respiratory-research.com/content/15/1/51
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Figure 3 ATO inhibits Smad2/Smad3 and Akt phosphorylation but does not affect p38 phosphorylation. (A-B) NHLFs were pre-treated
with ATO for 24 hrs. Then cells were treated with TGF-β1 (1 ng/ml) for 30 mins. TGF-β1 did not affect total Smad2 and Smad3 expression, but did
increase their phosphorylation. TGF-β1 induced Smad2 and Smad3 phosphorylation were blocked by ATO. (C) NHLFs were pre-treated with ATO
for 24 hrs, and then washed 5 times with PBS to remove ATO from the media. Thereafter cells were exposed to TGF-β1 (1 ng/ml) for 30 mins.
The results indicate that the effects of ATO on TGF-β1 induced Smad2 and Smad3 phosphorylation are not due to disruption of the of the
TGF-β1 ligand. (D) NHLFs were pre-treated with ATO for 24 hrs., and then treated with TGF-β1 (1 ng/ml) for 12 hrs. Akt phosphorylation was
induced by TGF-β1 and this induction was diminished by ATO. (E) NHLFs were pre-treated with ATO for 24 hrs, then treated with TGF-β1
(1 ng/ml) for 30 mins. ATO increased TGF-β1 induced p38 phosphorylation. (F) TGF-β1 induces H2O2 in NHLFs. ATO at the indicated
concentrations did not induce H2O2, but did diminish TGF-β1-induced H2O2 production. (G) NHLFs were pre-treated with ATO for 24 hrs, then
treated with TGF-β1 (1 ng/ml) with or without H2O2 for 30 mins. Smad3 phosphorylation was up-regulated by H2O2. (H) TGF-β1 induced NOX-4
mRNA expression in NHLFs, whereas ATO at the indicated concentrations inhibited TGF-β1-induced NOX-4 mRNA expression. Western blot data
represents consistent trend in three independent repeats with the best image quality. RT-PCR data represent results from three independent
experiments with duplicate repeats. *P value < 0.05, **P value <0.01, ***P value < 0.001.
Luo et al. Respiratory Research 2014, 15:51 Page 8 of 14
http://respiratory-research.com/content/15/1/51phosphorylation reduced by ATO (Figure 3G). The
NADPH oxidase (NOX) proteins generate H2O2 by
transferring electrons to oxygen, and NOX-4 has been
reported to mediate myofibroblast differentiation
[25,26]. To determine how ATO regulates TGF-β1 in-
duced NOX-4 expression, NHLFs were pretreated with
ATO (10nM or 20nM) for 24 hrs and then treated with
TGF-β1 (1 ng/ml) for another 24 hrs. TGF-β1 induced a
marked up-regulation of NOX-4 mRNA (264.80 ± 19.29;
p < 0.05), however pre-treatment with ATO significantly
blunted this effect (119.50 ± 17.66 & 136.20 ± 28.32 vs.
264.80 ± 19.29; p < 0.05) (Figure 3H).Figure 4 TGF-β1 induced PAI-1, fibronectin and Smad3 phosphorylat
(20nM) for 24 hrs. Cytoplasmic and nuclear compartments were separated
cytoplasm and nucleus in response to ATO treatment. (B) Immunofluoresc
response to ATO treatment. (C) Wild type and PML-/- mouse embryonic fib
Fibronectin-EDA and PAI-1 protein expression was induced by TGF-β1 in W
treated with TGF-β1 (1 ng/ml) and cells were harvested at the indicated tim
level of phosphorylation was markedly decreased in PML -/- MEFs. Western
with the best image quality.ATO causes a reduction in PML protein and PML nuclear
bodies in NHLFs
ATO has been reported to degrade PML proteins and
PML nuclear bodies in various cancer cell lines [12], and
cytoplasmic PML (cPML) has been shown to play an es-
sential role in Smad-dependent TGF-β1 signaling [16].
To investigate whether ATO decreases PML protein ex-
pression in NHLFs, NHLFs were treated with ATO
(20nM) for 24 hrs. Both cytoplasmic and nuclear PML
were down-regulated by ATO (Figure 4A). PML nuclear
bodies are dynamic structures in the nucleus that are re-
sponsible for transcription regulation, DNA damageion are impaired in PML -/- MEFs. (A) NHLFs were treated with ATO
and extracted. PML protein expression was decreased in both the
ent staining shows that PML bodies in NHLFs were decreased in
roblasts (MEFs) were treated with TGF-β1 (1 ng/ml) for 24 hrs.
T-MEFs but not PML -/- MEFs. (D) Wild-type and PML -/- MEFs were
e points. Smad3 phosphorylation was induced in WT-MEFs and the
blot data represents consistent trend in three independent repeats
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bodies and interacts with other sumoylated proteins to
form PML nuclear bodies. NHLFs were treated with
ATO for 24 hrs to investigate whether ATO reduces
PML nuclear bodies in NHLFs, and immunofluores-
cent staining showed that PML body intensity was dra-
matically decreased in response to ATO treatment
(Figure 4B).PML is essential for TGF-β signaling in MEFs
To test whether PML is essential for TGF-β1 signaling
and Smad phosphorylation, wild type MEFs and PML -/-
MEFs were treated with TGF-β1 (1 ng/ml) for 24 hrs
and harvested for western blot analysis. TGF-β1 induced
PAI-1 and fibronectin protein expression in wild-type
MEFs; however the induction decreased in PML -/-
MEFs (Figure 4C). TGF-β1 induces the phosphorylation
of both Smad2 and Smad3 but the profibrotic effect in-
duced by TGF-β1 is largely dependent on Smad3 activa-
tion [27]. To investigate whether PML plays a role in
Smad3 activation, wild type MEFs and PML -/- MEFs
were treated with TGF-β1 (1 ng/ml) for the indicated
time points. Smad3 phosphorylation was induced by
TGF-β1 in the wild type MEFs and this event was mark-
edly decreased in PML -/- MEFs (Figure 4D).Figure 5 Daily injection of ATO reduces PML body in C57BL/6 mouse
administered to C57BL/6 mice (n = 7) as indicated. Bleomycin was administ
intra-peritoneal injection. (B) Mice were sacrificed 14 days after bleomycin
disrupted their formation, in mouse lungs. (C) Densitometric quantification
***P value < 0.001.ATO inhibits bleomycin induced lung fibrosis in C57BL/6
mice
The bleomycin model is a well-established model of pul-
monary fibrosis and is TGF-β1 dependent [28]. To
examine whether ATO inhibits bleomycin-induced fibro-
sis in vivo, ATO (1 mg/kg) and control diluent (PBS +
NaOH) were delivered to mice (5 groups, n = 7) by daily
intraperitoneal injection. In the pre-treatment group
ATO was started 2 days before bleomycin administra-
tion, and in the delayed treatment group ATO was
started 6 days after the bleomycin administration. Bleo-
mycin (2units/kg) and dilutent control (PBS) were given
by oropharyngeal administration. Mice were sacrificed
14 days after treatment with of bleomycin (Figure 5A).
Immunofluorescent staining showed that bleomycin in-
creased PML body intensity while ATO decreased this
effect in vivo (0.32 ± 0.08 & 0.37 ± 0.04 vs. 2.83 ± 0.16;
p < 0.05) (Figure 5B, 5C).
To evaluate the effects of ATO on level of fibrosis in-
duced by bleomycin, murine left lungs were homogenized
in liquid nitrogen and mRNA was harvested for RT-
qPCR. Type-I collagen mRNA expression was induced
by bleomycin whereas both pretreatment and delayed
ATO treatment reduced this induction (3.61 ± 0.47 &
3.15 ± 0.51 vs. 5.60 ± 0.42; p < 0.05) (Figure 6A). α-SMA
mRNA expression was not up-regulated by bleomycinlungs. (A) Bleomycin (2units/kg) and ATO (1 mg/kg) were
ered by oropharyngeal aspiration. ATO was administered daily by
administration. Bleomycin induced PML body formation, while ATO
of PML body intensity for Figure 5B. *P value < 0.05, **P value <0.01,
Figure 6 ATO inhibits bleomycin induced lung fibrosis phenotypes in C57BL/6 mice. (A, B) C57BL/6 mice were exposed to bleomycin and
ATO as described in Figure 5. Type-1 collagen and α-SMA mRNA expression were induced by bleomycin and this effect was diminished by ATO.
(C, D) Increased Type-I collagen protein expression in response to bleomycin treatment was blocked by ATO, and was statistically significant. (E)
Representative histology showing that bleomycin induced inflammation and collagen deposition in mouse lungs, and these features were
reduced by ATO treatment. (F) Total collagen expression on lung sections was evaluated using the Aperio software scanning system. Bleomycin
induced total collagen expression and ATO treatment decreased this effect.
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However the expression level of α-SMA was signifi-
cantly decreased both groups treated with ATO (0.84 ±
0.07 & 0.85 ± 0.05 vs. 1.31 ± 0.12; p < 0.05) (Figure 6B).
Total protein was also harvested to evaluate lung type-I
collagen protein expression. Bleomycin increased type-I
collagen protein expression, while the pretreatment and
delayed treatment of ATO decreased its expression(Figure 6C-D). To assess lung histological changes in-
duced by bleomycin, Mason’s trichrome staining was
applied to lung sections. Bleomycin induced robust
collagen deposition in lungs. In contrast, pretreatment
and delayed treatment with ATO appeared to preserve
lung architecture (Figure 6E, Additional file 2: Figure
S2). Tissue slides were scanned using an Aperio slide
scanner to quantify total collagen expression. Bleomycin
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pretreatment and delayed treatment with ATO diminished
this effect (1.31 ± 0.02 & 1.23 ± 0.06 vs. 1.61 ± 0.03; p <
0.05) (Figure 6F).
In summary, ATO inhibits TGF-β1 induced fibroblast
to myofibroblast differentiation by blocking multiple sig-
naling pathways including Smad2, Smad3 and Akt phos-
phorylation, PML expression, NOX-4 mRNA and H2O2
generation in vitro (Figure 7). Moreover, low dose ATO
blocks bleomycin-induced lung fibrosis, and to date
there is evidence that this correlates with a reduction in
PML bodies.
Discussion
In this study, we have demonstrated that ATO inhibits
TGF-β1 induced FMD, as well as type-I collagen and α-
SMA expression. We also have shown that ATO reduces
bleomycin-mediated pulmonary fibrosis in mice. As for
the mechanism, we found that ATO down-regulates
Smad2/Smad3 and Akt phosphorylation in vitro. We
also showed that ATO decreased PML expression in
NHLFs, which could in turn regulate Smad3 phosphoryl-
ation. ATO has very recently been shown to be protect-
ive against bleomycin- induced fibrosis by subcutaneous
injection in BALB/c mice [29], which further supports
our hypothesis that ATO could be used as an anti-
fibrotic agent. Our study provides more detailed and
profound description of ATO’s anti-fibrotic effect byFigure 7 Depiction of in vitro experiments summarizing how
ATO regulates TGF-β1 signaling. ATO blocks TGF-β1 induced
fibroblast to myofibroblast differentiation by suppressing Smad2,
Smad3 and Akt phosphorylation. ATO also blocks TGF-β1 induced
NOX-4 mRNA expression and therefore abrogates TGF-β1-induced
H2O2. Furthermore, ATO degrades PML bodies and suppresses PML
protein expression, which regulates Smad3 phosphorylation and may
play an important role in the pathogenesis of pulmonary fibrosis.illustrating the mechanisms in vitro, and employs a 5-
times lower dose (1 mg/kg) of ATO, as well as, a more
bleomycin more susceptible mouse strain for the in vivo
studies [30]. What is more, our experimental design in-
cluded early and late administration of ATO following
lung injury, and makes an association with PML body
expression.
The dose of ATO is critical for its potential thera-
peutic application for the treatment of pulmonary fibro-
sis. At concentrations in the micromolar range, ATO
induces ROS and promotes apoptosis for fibroblasts and
other primary cells [22,31-33]. ATO can also induce
acute airway epithelial injury by altering ATP-dependent
Ca2+ signaling [34]. Furthermore, intravenous injection
of ATO (1 mg/kg) was reported to induce cardiac fibro-
sis [35]. However, ATO concentration in the nanomolar
range, as we used in this study, is less toxic. The MTT
assay indicates that ATO at 10nM and 20nM does not
change the NHLF viability. The report of cardiac fibrosis
had not been published at the time we conducted our
in vivo experiments, and although we did not note a car-
diac effect on chest dissection we were not specifically
looking for one. ROS, especially H2O2, are considered to
be profibrogenic and are induced by TGF-β1 through a
mechanism that involves up-regulation of NOX-4 activ-
ity [26]. However, ATO at 10nM and 20nM did not in-
duce H2O2, but conversely blocked TGF-β1 induced
NOX-4 mRNA and H2O2 expression. In addition, in the
ATO treatment alone group, there were no observed un-
toward histological changes. Of relevance, the concen-
tration we used in our study is several orders of
magnitude lower than the clinical application of ATO
for the treatment of APL [36].
Fibroblast to myofibroblast differentiation (FMD) is a
crucial step for the genesis of myofibroblasts. Myofibro-
blasts are the effecter cells for producing extra-cellular
matrix in fibroblastic foci which lead to loss of alveolar
function of IPF lungs [37]. Myofibroblasts secrets α-
SMA, a stress fiber not only affects the compliance of
lungs but also works as a signal transduction molecule
to regulate extracellular matrix proteins production [3].
Myofibroblasts also contribute to abnormal epithelial
functions and induce epithelial apoptosis by secreting
pro-inflammatory cytokines [38]. Instead of directly in-
ducing apoptosis of fibroblasts, we have shown that low
dose of ATO blocked expression of multiple TGF-β1-
induced myofibroblast markers as well as mRNA levels
of potent profibrotic cytokines and proteins such as
CTGF and PAI-1.
Smad and Akt activation are two key pathways in-
volved in the development of TGF-β1-induced fibro-
genic phenotypes. A previous study has shown that ATO
at concentrations of 10 μM diminishes Smad3 protein
expression [11]. Although knocking down basal Smad3
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duced FMD, loss of Smad3 has been reported to correl-
ate with enlargement of airspaces and development of
emphysema [27]. In this study, we show that ATO in the
nanomolar range inhibits TGF-β1 induced Smad3 phos-
phorylation, but does not decrease Smad3 expression.
ATO has also been reported to inhibit Akt phosphoryl-
ation at a concentration of 3 μM in lymphoma B cells
[21]. Consistent with that study, we observed that a low
concentration of ATO inhibits TGF-β1 induced Akt
phosphorylation in NHLFs. The experiment in which
ATO was washed away prior to adding TGF-β1 excludes
the possibility of TGF-β1 ligand inactivation as an ex-
planation for the inhibition of Smad and Akt phorphory-
lation. Moreover, ATO does not inhibit phosphorylation
in a global level, as the experimental data show that Erk
and p38 phosphorylation are not diminished in response
to ATO.
To investigate how Smad3 phosphorylation is affected
by ATO, we focused on PML, a protein reported to be
degraded by ATO [12]. Consistent with a previous study
[16], we found that TGF-β1-induced PAI-1 and fibro-
nectin expression as well as Smad3 phosphorylation
were all impaired in PML -/- MEFs. To further test our
hypothesis that PML knockdown by ATO may be re-
sponsible for an impaired TGF-β1 signaling in NHLFs, a
“rescue” experiment to transfect PML plasmid into
NHLFs in an attempt to restore TGF-β1 signaling was
considered. However, ATO can efficiently induce the
oligomerization of PML, which promotes its ubiquitina-
tion and degradation [39]. Thus, we did not pursue this
approach because exogenous PML would be expected to
be degraded by ATO in a similar manner. In addition to
the important role of cPML in TGF-β1 signaling, PML
may have profound impact on the pathogenesis of IPF
via induction of cellular senescence through interactions
with p53 and Rb [40]. Accelerated epithelial senescence
has been observed in IPF lungs compared to control
lungs [40]. Furthermore, PML functions as a negative
regulator of hTERT and therefore contributes to short
telomere length [41], and short telomeres have been re-
ported to be a risk factor for IPF [33,42]. Taken together,
PML may play a key role in the pathogenesis of IPF, but
further experiments will need to be conducted to test
this concept. In addition to PML, we have also shown
that H2O2 might also play a role in ATO’s reduction
on TGF-β1 induced Smad3 phosphorylation. H2O2
(100 μM) partially restored ATO reduced Smad3 phos-
phorylation. How ATO regulates H2O2 and Nox4 ex-
pression is an area of interest to us for future studies.
Lastly we have shown that ATO inhibits bleomycin-
induced fibrosis in vivo. We have shown that 1 mg/kg of
ATO is able to significantly reduce the expression of
PML bodies in C57BL/6 mouse lungs, as it blocksbleomycin induced type-1 collagen, and diminishes the
basal level of α-SMA expression in mouse lungs. The de-
layed treatment group has a slightly better effect com-
pared with the pre-treatment group. One possible
explanation for this may be associated with the massive
DNA damage induced by bleomycin to the epithelial
cells [28] and PML bodies are actively involved in the
DNA repair process. Thus, the absence of PML bodies
at the time of DNA injury could lead to sustained epi-
thelial cell dysfunction and possibly a higher level of
pro-inflammatory cytokines [14]. Future experiments,
are planned that will employ PML KO mice in murine
models of pulmonary fibrosis.
Conclusions
In summary, this work demonstrates that ATO effect-
ively inhibits TGF-β1 induced FMD in vitro and reduces
lung fibrogenesis in vivo. Although the ATO concentra-
tions employed in these experiments were low and ATO
is already an FDA approved drug, it is unclear whether
or not trials using low dose ATO for the treatment of re-
calcitrant and deadly diseases such as IPF would be con-
sidered an acceptable form of therapy.
Additional files
Additional file 1: Figure S1. ATO inhibits TGF-β1 induced fibrotic
proteins expression in control and IPF lung fibroblasts as well as
diminishing established fibrotic responses in NHLFs. (A) Lung fibroblasts
extracted from 2 control patients were serum starved overnight and
treated with ATO (10nM, 20nM) for 24 hrs, then treated with TGF-β1
(1 ng/ml) for 24 hrs. α-SMA, and Collagen-1 were induced by TGF-β1,
and ATO inhibited TGF-β1’s effect. (B) ATO blocked TGF-β1 (1 ng/ml)
induced α-SMA and Collagen-1expression in lung fibroblasts derived from
2 patients with IPF. Data for both part A and B are representative of
consistent effects in both cell lines. (C) NHLFs were treated with TGF-β1
(1 ng/ml) for 24 hrs., then exposed to ATO (10nM, 20nM) for another
24 hrs. ATO blocked TGF-β1 induced α-SMA and Collagen-1 expression.
Additional file 2: Figure S2. Representative histology of mouse lungs
in response to bleomycin and ATO treatment. Bleomycin (2units/kg) and
ATO (1 mg/kg) were administered to C57BL/6 mice (n = 7) as described
in the methods section. Mice were sacrificed 14 days after bleomycin
administration. Representative histology (trichrome staining) illustrating
that bleomycin induced lung inflammation and fibrosis was reduced by
ATO treatment.
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